Angiotensin type 1 receptor expression and interleukin-8 production in polymorphonuclear leukocytes of patients with peripheral arterial disease.
We investigated angiotensin type 1 receptor (AT1R) expression and interleukin-8 (IL-8) productions in polymorphonuclear leukocytes obtained from patients with peripheral arterial disease (PAD) undergoing femoral endarterectomy. Subjects at high cardiovascular risk (high-risk subjects, HRS) and healthy controls (HC) were also enrolled. To this end, patients with PAD were studied 1 month before surgery, at the time of surgery, and 3 and 6 months after surgery. Polymorphonuclear leukocytes were obtained from venous blood and evaluated for AT1R expression at messenger RNA (mRNA) and protein level and IL-8 production (by means of enzyme-linked immunosorbent assay). At baseline, AT1R membrane expression was similar in cells from patients with PAD, HRS, and HC, whereas AT1R mRNA was similar in patients with PAD and HC and higher in HRS. During the follow-up period, AT1R expression progressively decreased both on the cell membrane and at the mRNA level. Both resting and stimulated production of IL-8 was lower in patients with PAD in comparison to HC and HRS and did not change during the follow up period. In PAD patients, femoral endarterectomy is associated with reduction of AT1R expression however with no apparent effect on IL-8 production. The relevance of such effects for cardiovascular protection deserves consideration.
Marino
Franca
F
Department of Clinical Medicine, Section of Experimental and Clinical Pharmacology, University of Insubria, Varese VA, Italy. franca.marino@uninsubria.it
Guasti
Luigina
L
Tozzi
Matteo
M
Consuelo Maio
Ramona
R
Castiglioni
Luana
L
Rasini
Emanuela
E
Schembri
Laura
L
Maroni
Lorenzo
L
Legnaro
Massimiliano
M
De Leo
Alessandra
A
Piffaretti
Gabriele
G
Castelli
Patrizio
P
Venco
Achille
A
Lecchini
Sergio
S
Cosentino
Marco
M
D000368:Aged; D000369:Aged, 80 and over; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D001054:Apolipoproteins A / Q000097:blood; D001055:Apolipoproteins B / Q000097:blood; D050197:Atherosclerosis / Q000097:blood* / Q000188:drug therapy / Q000601:surgery; D000069059:Atorvastatin; D002318:Cardiovascular Diseases / Q000097:blood; D016022:Case-Control Studies; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D004691:Endarterectomy; D005260:Female; D005263:Femoral Artery / Q000601:surgery; D015870:Gene Expression / Q000187:drug effects / Q000235:genetics; D006538:Heptanoic Acids / Q000627:therapeutic use; D006801:Humans; D016209:Interleukin-8 / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism*; D016491:Peripheral Vascular Diseases / Q000097:blood* / Q000188:drug therapy / Q000601:surgery; D011758:Pyrroles / Q000627:therapeutic use; D044140:Receptor, Angiotensin, Type 1 / Q000235:genetics / Q000378:metabolism*; D014280:Triglycerides / Q000097:blood
D000924:Anticholesteremic Agents; D001054:Apolipoproteins A; D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D006538:Heptanoic Acids; D016209:Interleukin-8; D011758:Pyrroles; D044140:Receptor, Angiotensin, Type 1; D014280:Triglycerides; D009240:N-Formylmethionine Leucyl-Phenylalanine; D002784:Cholesterol; D000069059:Atorvastatin